Table 4.
Primary IC50 ± SD (μM) | |||
---|---|---|---|
SUM149 | rSUM149 | rrSUM149 | |
Fludarabine | 2.1 ± 1.1 | 1.7 ± 0.8 | 1.4 ± 0.9 |
Mitoxantrone | 2.5 ± 0.6 | 11.4 ± 1.3 | 3.8 ± 3.4 |
Sorafenib | 4.5 ± 0.4 | 14.6 ± 3.1 | 78 ± 16 |
Sunitinib | 5.0 ± 0.8 | >25 | 7.05 ± 6.3 |
Gefitinib | 6.2 ± 2.3 | >50 | 28 |
Vorinostat | 8.9 ± 4.9 | 6.2 ± 0.6 | 2.75 ± 2.1 |
Lapatinib | 9.0 ± 0.3 | >50 | 9.1 |
Mitomycin | 9.1 ± 0.4 | 18.5 ± 0.8 | 6.2 ± 0.4 |
Bleomycin | 13.8 ± 2.0 | >50 | 9.5 |
Capecitabine | 15.0 ± 9.5 | >50 | 26 ± 1.4 |
Doxorubicin, bortezomib, dactinomycin, plicamycin and daunorubicin all had IC50 values <0.2 μM on all three isogenic cell lines.